Early post-approval results of gene therapy for RPE65-mediated retinal dystrophy with Luxturna (voretigene neparvovec) at Massachusetts Eye and Ear

2019 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []